<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871855</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1702-I-101</org_study_id>
    <nct_id>NCT03871855</nct_id>
  </id_info>
  <brief_title>A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination
      with Camrelizumab among advanced solid tumor subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with DLTs</measure>
    <time_frame>Approximately 28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR: Percentage of Participants With a CR or PR</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SHR -1702 using Common Terminology Criteria for Adverse Events.</measure>
    <time_frame>Dose Escalation Part -- Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by the presence of anti-drug antibodies</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile as assessed by receptor occupancy</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Maximum Concentration (Cmax)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUC, 0 to infinity</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clearance (CL)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmin at steady state (Cmin,ss)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax at steady state (Cmax, ss)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: terminal half-life (t1/2)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>A:SHR-1702 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1702 given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B:SHR-1702 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1702 given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C:SHR-1702 and Camrelizumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1702 and Camrelizumab given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D:SHR-1702 and Camrelizumab Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1702 and Camrelizumab given intravenously (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1702</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>A:SHR-1702 Dose Escalation</arm_group_label>
    <arm_group_label>B:SHR-1702 Dose Expansion</arm_group_label>
    <arm_group_label>C:SHR-1702 and Camrelizumab Dose Escalation</arm_group_label>
    <arm_group_label>D:SHR-1702 and Camrelizumab Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>C:SHR-1702 and Camrelizumab Dose Escalation</arm_group_label>
    <arm_group_label>D:SHR-1702 and Camrelizumab Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced relapsed/refractory solid tumors

          -  Must have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group
             (ECOG) scale

          -  Have an estimated life expectancy of 12 weeks, in judgement of the investigatorï¼›

          -  Must have at least 1 measurable lesion assessable using standard techniques by
             Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

          -  Adequate hematologic and organ function

          -  Signed inform consent form

        Exclusion Criteria:

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan.

          -  Significant cardiovascular disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring

          -  History of autoimmune disease.

          -  Subjects with a condition requiring systemic treatment with either corticosteroids
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of first administration of study treatment. Inhaled or topical steroids, and
             adrenal replacement steroid are permitted in the absence of active autoimmune disease.

          -  Positive test result for human immunodeficiency virus (HIV); Active hepatitis B or
             hepatitis C

          -  Active or untreated central nervous system (CNS) metastases

          -  Active infection within 2 weeeks

          -  History of severe (or known) hypersensitivity to chimeric or humanized antibodies or
             fusion proteins

          -  Prior allogeneic bone marrow transplantation or solid organ transplant

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the subject's participation
             for the full duration of the study, or is not in the best interest of the subject to
             participate, in the opinion of the treating investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Zou,</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu HengRui Medicine Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Zou, MD</last_name>
    <phone>021-68868570</phone>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shunchang Jiao</last_name>
    </contact>
    <contact_backup>
      <last_name>Yi Hu</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

